The relative bioavailability and metabolism of bisphenol A in rats is dependent upon the route of administration.
Bisphenol A (BPA) is used to produce polymers for food contact applications, thus there is potential for oral exposure of humans to trace amounts via the diet. BPA was weakly estrogenic in screening assays measuring uterine weight/response, although much higher oral doses of BPA were required to elicit a uterotropic response as compared to other routes of administration. The objective of this study was to determine if a route dependency exists in the pharmacokinetics and metabolism of 14C-labeled BPA following single oral (po), intraperitoneal (ip), or subcutaneous (sc) doses of either 10 or 100 mg/kg to Fischer 344 rats. Results indicated a marked route dependency in the pharmacokinetics of BPA. The relative bioavailability of BPA and plasma radioactivity was markedly lower following oral administration as compared to sc or ip administration. The major fraction of plasma radioactivity following oral dosing was the monoglucuronide conjugate of BPA (68-100% of plasma radioactivity). BPA was the major component in plasma at Cmax following sc or ip administration exceeded only by BPA-monoglucuronide in females dosed ip. Up to four additional unidentified metabolites were present only in the plasma of animals dosed ip or sc. One of these, found only following ip administration, was tentatively identified as the monosulfate conjugate of BPA. The monoglucuronide conjugate was the major urinary metabolite; unchanged BPA was the principal component excreted in feces. These results demonstrated a route dependency of BPA bioavailability in rats, with oral administration resulting in the lowest bioavailability, and offer an explanation for the apparent route differences in estrogenic potency observed for BPA.
Pottenger
L H
LH
Toxicology and Environmental Research and Consulting, Dow Europe, Horgen, Switzerland.
Domoradzki
J Y
JY
Markham
D A
DA
Hansen
S C
SC
Cagen
S Z
SZ
Waechter
J M
JM
D000042:Absorption; D000284:Administration, Oral; D000395:Air Pollutants, Occupational / Q000378:metabolism / Q000493:pharmacokinetics*; D000818:Animals; D001559:Benzhydryl Compounds; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D004032:Diet; D004968:Estrogens, Non-Steroidal / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics*; D005260:Female; D006003:Glycogen / Q000378:metabolism; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D008297:Male; D013058:Mass Spectrometry; D010636:Phenols / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics*; D010865:Pilot Projects; D051381:Rats; D011916:Rats, Inbred F344; D014599:Uterus / Q000187:drug effects / Q000378:metabolism; D000098826:Bisphenol A Compounds
D000395:Air Pollutants, Occupational; D001559:Benzhydryl Compounds; D004968:Estrogens, Non-Steroidal; D006003:Glycogen; D010636:Phenols; C006780:bisphenol A; D000098826:Bisphenol A Compounds